Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multi-specific therapeutic
Biotech
Pfizer pens $10B, 12-drug deal with Innovent
Pfizer is paying $650 million upfront and proposing four discovery programs, while Innovent is contributing eight early-stage assets.
Nick Paul Taylor
May 29, 2026 4:05am
AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer
Jul 10, 2025 9:01am
Daiichi gins up antibody research collab with German institute
Jan 14, 2025 3:44pm
AbbVie pays $65M for options on EvolveImmune's T-cell engagers
Oct 31, 2024 10:00am
Purple snags Immunorizon's tri-specific antibodies in small M&A
Feb 2, 2023 10:20am
Amgen avoids 'low-hanging fruit' in tackling undruggable targets
Jun 29, 2022 3:00pm
